These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14654565)

  • 1. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
    Mensah-Osman EJ; Al-Katib AM; Mohammad RM
    Clin Cancer Res; 2003 Nov; 9(15):5794-7. PubMed ID: 14654565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
    Mensah-Osman EJ; Al-Katib AM; Dandashi MH; Mohammad RM
    Mol Cancer Ther; 2002 Dec; 1(14):1315-20. PubMed ID: 12516964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
    Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
    Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
    Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
    Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
    Mensah-Osman E; Al-Katib A; Dandashi M; Mohammad R
    Int J Oncol; 2003 Dec; 23(6):1637-44. PubMed ID: 14612935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
    Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
    J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
    Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R
    Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice.
    Polin L; White K; Kushner J; Paluch J; Simpson C; Pugh S; Edelstein MK; Hazeldine S; Fontana J; LoRusso P; Horwitz JP; Corbett TH
    Invest New Drugs; 2002 Feb; 20(1):13-22. PubMed ID: 12003190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.
    al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR
    Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antitumor activity of XK469 (NSC 656889).
    LoRusso PM; Parchment R; Demchik L; Knight J; Polin L; Dzubow J; Behrens C; Harrison B; Trainor G; Corbett TH
    Invest New Drugs; 1998-1999; 16(4):287-96. PubMed ID: 10426660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
    Hazeldine ST; Polin L; Kushner J; Paluch J; White K; Edelstein M; Palomino E; Corbett TH; Horwitz JP
    J Med Chem; 2001 May; 44(11):1758-76. PubMed ID: 11356111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
    Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
    Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4.
    Hazeldine ST; Polin L; Kushner J; White K; Corbett TH; Horwitz JP
    Bioorg Med Chem; 2005 Jun; 13(12):3910-20. PubMed ID: 15911307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence.
    Reiners JJ; Kleinman M; Joiakim A; Mathieu PA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):796-806. PubMed ID: 19066341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.
    Ding Z; Parchment RE; LoRusso PM; Zhou JY; Li J; Lawrence TS; Sun Y; Wu GS
    Clin Cancer Res; 2001 Nov; 7(11):3336-42. PubMed ID: 11705845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
    Hazeldine ST; Polin L; Kushner J; White K; Bouregeois NM; Crantz B; Palomino E; Corbett TH; Horwitz JP
    J Med Chem; 2002 Jul; 45(14):3130-7. PubMed ID: 12086498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Waldenström's macroglobulinemia effectively treated with chronic daily oral administration of low-dose etoposide].
    Itoh K; Shimada T; Horibe T; Kawai N; Sakata T; Fukuda M; Murohashi I; Bessho M; Takeuchi H; Hirashima K
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2131-4. PubMed ID: 9838919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Part 3: synthesis and biological evaluation of some analogs of the antitumor agents, 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid, and 2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid.
    Hazeldine ST; Polin L; Kushner J; White K; Corbett TH; Biehl J; Horwitz JP
    Bioorg Med Chem; 2005 Feb; 13(4):1069-81. PubMed ID: 15670915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.